Last reviewed · How we verify
Continuation of OMA treatment
Continuation of OMA treatment is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently FDA-approved.
At a glance
| Generic name | Continuation of OMA treatment |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Continuation of OMA treatment CI brief — competitive landscape report
- Continuation of OMA treatment updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI
Frequently asked questions about Continuation of OMA treatment
What is Continuation of OMA treatment?
Continuation of OMA treatment is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris.
Who makes Continuation of OMA treatment?
Continuation of OMA treatment is developed and marketed by Assistance Publique - Hôpitaux de Paris (see full Assistance Publique - Hôpitaux de Paris pipeline at /company/assistance-publique-h-pitaux-de-paris).
What development phase is Continuation of OMA treatment in?
Continuation of OMA treatment is FDA-approved (marketed).